J&J/Basilea’s Ceftobiprole Gets Another Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA stops the investigational antibiotic’s six-month review clock for additional clinical site audits, data integrity review.
You may also be interested in...
Basilea Takes On Partner J&J In Arbitration Claim Over Ceftobiprole Delays
In an era where most product- and innovation-hungry big pharma firms have been desperately promoting themselves as "best partners," it is perhaps easy to forget what can go wrong when a biotech entrusts its asset to a larger firm
Basilea Takes On Partner J&J In Arbitration Claim Over Ceftobiprole Delays
In an era where most product- and innovation-hungry big pharma firms have been desperately promoting themselves as "best partners," it is perhaps easy to forget what can go wrong when a biotech entrusts its asset to a larger firm
FDA Updating Antibiotic Guidances, But Is It Too Late For Some Sponsors?
It was supposed to be a year with a wealth of novel antibiotics, but regulatory concerns turned 2008 from a year of banner antibiotic approvals into a sizeable crop of action letters. Now the delays are taking a serious toll, causing some sponsors to drastically restructure in the face of uncertain and evolving regulatory standards